Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ute Hegenbart

Showing results (141-150 of 203) with videos related to

Pageof 21
Sort By:
Blood|June 29, 2010
Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assayArnt V Kristen, Evangelos Giannitsis, Stephanie Lehrke, et al.
The FEBS Journal|April 25, 2023
Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myelomaNatalie Berghaus, Sarah Schreiner, Alexandra M Poos, et al.
Blood|February 12, 2011
Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)Tilmann Bochtler, Ute Hegenbart, Christiane Heiss, et al.
British Journal of Haematology|January 25, 2003
Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remissionLyle C Feinstein, Brenda M Sandmaier, Ute Hegenbart, et al.
Ejhaem|August 19, 2024
HOVON 104, long-term follow-up of bortezomib-dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patientsMonique C Minnema, Kazem Nasserinejad, Ute Hegenbart, et al.
Blood|February 29, 2020
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuriaChristoph R Kimmich, Tobias Terzer, Axel Benner, et al.
Haematologica|May 20, 2017
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow upUte Hegenbart, Tilmann Bochtler, Axel Benner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-upBo Björkstrand, Simona Iacobelli, Ute Hegenbart, et al.
Nature Medicine|March 12, 2026
Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosisStephan A Kaeser, Stephanie A Schultz, Anna Hofmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2008
Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study GroupJohannes Schetelig, Martin Bornhäuser, Christoph Schmid, et al.
Pageof 21

Showing results (141-150 of 203) with videos related to

Sort By:
Pageof 21
Blood|June 29, 2010
Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assayArnt V Kristen, Evangelos Giannitsis, Stephanie Lehrke, et al.
The FEBS Journal|April 25, 2023
Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myelomaNatalie Berghaus, Sarah Schreiner, Alexandra M Poos, et al.
Blood|February 12, 2011
Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)Tilmann Bochtler, Ute Hegenbart, Christiane Heiss, et al.
British Journal of Haematology|January 25, 2003
Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remissionLyle C Feinstein, Brenda M Sandmaier, Ute Hegenbart, et al.
Ejhaem|August 19, 2024
HOVON 104, long-term follow-up of bortezomib-dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patientsMonique C Minnema, Kazem Nasserinejad, Ute Hegenbart, et al.
Blood|February 29, 2020
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuriaChristoph R Kimmich, Tobias Terzer, Axel Benner, et al.
Haematologica|May 20, 2017
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow upUte Hegenbart, Tilmann Bochtler, Axel Benner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-upBo Björkstrand, Simona Iacobelli, Ute Hegenbart, et al.
Nature Medicine|March 12, 2026
Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosisStephan A Kaeser, Stephanie A Schultz, Anna Hofmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2008
Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study GroupJohannes Schetelig, Martin Bornhäuser, Christoph Schmid, et al.
Pageof 21